Over the last 7 days, the United States market has risen 1.9%, contributing to a 24% increase over the past year, with earnings forecasted to grow by 15% annually. In such a dynamic environment, identifying high growth tech stocks involves looking for companies that demonstrate strong innovation potential and scalability to capitalize on these favorable market conditions.
Top 10 High Growth Tech Companies In The United States
| Name | Revenue Growth | Earnings Growth | Growth Rating |
|---|---|---|---|
| Marker Therapeutics | 61.33% | 65.71% | โ โ โ โ โ โ |
| Palantir Technologies | 26.84% | 31.25% | โ โ โ โ โ โ |
| 22.20% | 27.96% | โ โ โ โ โ โ | |
| Sandisk | 30.23% | 46.19% | โ โ โ โ โ โ |
| Gorilla Technology Group | 54.35% | 95.02% | โ โ โ โ โ โ |
| Tenaya Therapeutics | 58.52% | 60.10% | โ โ โ โ โ โ |
| Kiniksa Pharmaceuticals International | 14.59% | 33.39% | โ โ โ โ โ โ |
| Zscaler | 15.93% | 48.88% | โ โ โ โ โ โ |
| Procore Technologies | 12.08% | 99.98% | โ โ โ โ โ โ |
| KVH Industries | 25.44% | 135.75% | โ โ โ โ โ โ |
Click here to see the full list of 73 stocks from our US High Growth Tech and AI Stocks screener.
We're going to check out a few of the best picks from our screener tool.
Simply Wall St Growth Rating: โ โ โ โ โโ
Overview: ADMA Biologics, Inc. is a biopharmaceutical company that focuses on developing, manufacturing, and marketing specialty plasma-derived biologics for treating immune deficiencies and infectious diseases, with a market cap of $2.17 billion.
Operations: The company's primary revenue stream is ADMA Biomanufacturing, generating $493 million, while Plasma Collection Centers contribute $17.03 million.
ADMA Biologics, despite a challenging year with a 25.7% decline in earnings, is positioning for recovery with anticipated revenue growth of 17.6% annually, outpacing the US market average of 10.4%. This biotech firm's commitment to innovation is underscored by its R&D investments, crucial for staying competitive against an industry growth rate of 40.2%. The recent executive changes and strategic financial guidance suggest…